Skyrizi® Pre-filled Cartridge with Injector for Crohn's and Ulcerative Colitis

Skyrizi prefilled cartridge without insurance details can help you plan maintenance treatment. This on-body injector cartridge provides subcutaneous risankizumab for adult Crohn’s disease and ulcerative colitis after induction. Our platform supports US delivery from Canada so you can compare access options in one place.

What Skyrizi® Is and How It Works

CanadianInsulin.com is a prescription referral platform. We verify prescriptions with your prescriber when required, and licensed Canadian pharmacies dispense your order.

This medicine contains risankizumab, a monoclonal antibody targeting the p19 subunit of interleukin-23 (IL‑23). By blocking IL‑23 signaling, it may reduce gut inflammation associated with moderate to severe inflammatory bowel disease. The on-body device is designed for hands-free subcutaneous delivery at scheduled intervals.

The phrase risankizumab prefilled cartridge with injector refers to this cartridge-and-injector presentation used for maintenance dosing. Induction treatment is given first by intravenous infusion under clinical supervision, then ongoing subcutaneous doses follow on the schedule your prescriber selects.

Who It’s For

This treatment is approved for adults with moderate to severe Crohn’s disease and ulcerative colitis who have completed IV induction. The cartridge format supports ongoing maintenance to help sustain response. Your clinician will confirm suitability based on disease severity, prior therapies, and infection risk.

Some patients should not use the therapy. People with active, serious infections should avoid starting until resolved. Those with latent or active tuberculosis require evaluation and management before treatment. The phrase Skyrizi injector cartridge for Crohn’s disease describes its intended maintenance role; for ulcerative colitis, the same cartridge applies after induction.

Other approved indications for the active ingredient include plaque psoriasis and psoriatic arthritis, though these often use different subcutaneous presentations. For dermatologic conditions, see our category pages on Psoriasis and Psoriatic Arthritis for broader context.

Dosage and Usage

Follow the Patient Information and Instructions for Use included with your device. After IV induction, the cartridge-and-injector is administered on a regular maintenance schedule chosen by your prescriber. Many adults receive doses every 8 weeks, but your plan may differ based on response and tolerance.

The Skyrizi maintenance dose cartridge is designed to deliver a full dose automatically after placement on the skin. Use clean, intact skin on the abdomen or thigh, avoiding scars, moles, tattoos, and active skin conditions. Rotate sites with each dose. Do not press, squeeze, or tape the device during delivery. If you are unsure whether a complete dose was delivered, follow the device’s troubleshooting guide and contact your care team.

Before each scheduled administration, review the device checklist. Confirm the cartridge is clear to slightly yellow and free of particles; do not use if cloudy or discolored. Inspect the injector for damage and expiration date. Allow refrigerated supplies to reach room temperature as directed in the Instructions for Use before application.

Strengths and Forms

The maintenance cartridge for inflammatory bowel disease is commonly available as a risankizumab 360 mg cartridge paired with an on-body injector. Other dosage forms exist, including prefilled syringes and pens for dermatologic indications, which are not interchangeable with the cartridge and injector.

Availability can vary by pharmacy and region. Your prescription will specify the presentation and strength. If you have questions about interchangeability, consult your prescriber or pharmacist before attempting any change in device or strength.

Missed Dose and Timing

If you miss a scheduled dose, take it as soon as you remember unless it is close to the next dose. In that case, follow your prescriber’s guidance and the product’s patient instructions. Do not administer two doses at once to make up for a missed dose.

If the on-body injector stops or appears to malfunction during delivery, consult the Instructions for Use. Record the time and any device indicator lights. Save the device and contact your prescriber or the device support line for next steps.

Storage and Travel Basics

Keep the cartridge in its original carton in the refrigerator, protected from light. Do not freeze. If a carton was frozen, do not use it. Allow the device to reach room temperature per the label before use; do not warm it with external heat sources. Keep out of reach of children and pets.

When traveling, transport in an insulated container with cool packs to maintain recommended temperatures. Carry documentation of your prescription and keep supplies in your carry-on during air travel. Plan for security screening and allow extra time to explain medical devices. We use temperature-controlled handling when required.

Do not shake the cartridge. Do not use if dropped on a hard surface or if the device shows cracks, leaks, or missing components. Dispose of expired or damaged units according to local regulations.

Pen Handling and Sharps Disposal

This product uses an on-body injector rather than a manual pen. Review the illustrated steps in the Instructions for Use before your first dose. Select a clean application site, cleanse with an alcohol wipe, and let it dry completely. Attach the cartridge only when ready to dose. Start the device as directed and remain still while delivery completes.

After use, place the empty cartridge and any exposed needles in a puncture-resistant, FDA-cleared sharps container. Do not recap needles or discard devices in household trash. When the container is nearly full, follow community guidelines for sharps disposal or pharmacy take-back programs.

Benefits

Maintenance dosing with an on-body injector can reduce clinic visits after IV induction. Scheduled, hands-free delivery may aid adherence. Less frequent injections compared to some regimens can be convenient for people managing travel or work.

The class targets a key inflammatory pathway involved in bowel inflammation. By focusing on IL‑23, therapy may spare other immune functions compared with broader immunosuppressants. Your prescriber will align goals with objective measures such as symptoms, labs, and endoscopic findings.

Side Effects and Safety

• Injection-site reactions: redness, itching, or mild pain
• Upper respiratory symptoms: sore throat or stuffy nose
• Headache or fatigue
• Rash or hives
• Abdominal discomfort or nausea

Serious risks can include severe hypersensitivity, serious infections, and reactivation of tuberculosis. People with chronic or recurrent infections require careful assessment. Avoid live vaccines during treatment and shortly before starting. Tell your prescriber about any fever, cough, weight loss, night sweats, or other infection signs before each dose.

Drug Interactions and Cautions

Live attenuated vaccines may cause infection in immunomodulated patients; avoid them during therapy. Non-live vaccines may be given, but responses can vary. Discuss timing of immunizations before starting. Concomitant immunosuppressants and biologics may increase infection risk; your prescriber will coordinate therapy.

Baseline screening for latent tuberculosis is standard. Inform your care team about recent or planned surgery, chronic infections, or a history of hypersensitivity to monoclonal antibodies. If you become pregnant or plan to breastfeed, discuss benefits and risks, as human data are limited for the class.

For broader context on biologic selection and safety, you can review our article Ustekinumab vs Adalimumab, which discusses class considerations that may inform clinical conversations.

What to Expect Over Time

After the induction phase, ongoing subcutaneous maintenance aims to sustain response and reduce relapse risk. Some people notice steadier symptom control when doses are taken on schedule. Your provider may monitor stool frequency, pain, inflammatory markers, and endoscopic assessments over time.

Expect periodic re-evaluation. Dosing schedules, supportive care, and concomitant medications can change based on response or tolerability. Keep a dosing calendar and report any new symptoms promptly. Do not alter your schedule without clinical guidance.

Compare With Alternatives

Other biologics used for inflammatory bowel disease include ustekinumab and adalimumab. For some patients, Stelara Syringe offers a different mechanism targeting IL‑12/23. For others, tumor necrosis factor blockade with Humira may be considered. Choice depends on prior therapy, comorbidities, and clinician judgment.

Pricing and Access

Canadian pricing with reliable US fulfillment can offer value compared with local cash options. If you are comparing the Skyrizi prefilled cartridge price, review our transparent product listing and contact support with questions about prescriptions and refills. We provide availability details and coordination steps so you can plan ahead with your clinic.

We also curate education on savings programs and assistance that may apply to eligible patients. For occasional seasonal offers, visit our Promotions page. Orders are processed by licensed Canadian pharmacies and shipped to the United States. Ships from Canada to US services are available for qualifying prescriptions.

Availability and Substitutions

Supply can vary by strength and device. If the cartridge is unavailable, your prescriber may recommend an alternative biologic or a different presentation of the active ingredient, if appropriate. Do not substitute products or devices without explicit clinical approval.

Patient Suitability and Cost-Saving Tips

Good candidates include adults who completed induction, can self-manage an on-body device, and have no active serious infection. Those with uncontrolled chronic infections, untreated latent TB, or prior severe hypersensitivity may not be suitable. Your prescriber will review risks and benefits with you.

To manage expenses, consider multi-month supplies if permitted by your prescription and stability guidance. Set refill reminders to avoid missed doses due to supply gaps. Ask your clinic about manufacturer assistance or independent foundations, as appropriate. For broader condition support, see our Gastrointestinal category and condition pages for Crohn’s Disease and Ulcerative Colitis.

Questions to Ask Your Clinician

• Induction plan: which infusion dose and schedule
• Maintenance timing: interval, duration, and monitoring
• Device training: how to start, stop, and troubleshoot
• Vaccinations: which vaccines and when to receive them
• Infection risk: TB screening and sick-day guidance
• Travel: storage needs and documentation for flights
• Follow-up: labs, imaging, and endoscopy timing

Authoritative Sources

For complete prescribing information and device instructions, consult official sources:

• AbbVie product information and patient Instructions for Use on the manufacturer’s website (risankizumab injection), which describes indications and device specifics in detail. Manufacturer Prescribing Information
• FDA labeling and Medication Guide provide comprehensive safety and usage details for risankizumab-rzaa subcutaneous products. FDA DailyMed Label
• Health Canada’s Drug Product Database lists Canadian product information for risankizumab, including device presentations. Health Canada DPD

Order online with prompt, express, cold-chain shipping and clear US fulfillment coordination.

Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.